Skip to main content
Menu
Menu
Main navigation
Home
Education
Featured Topics
Acute Hepatic Porphyria
Agitation in Alzheimer Disease
COVID-19
Danon Disease
Depression Care 360
Diabetes
Diabetes Technology
Digital Health Solutions in Diabetes
Dry Eye Disease
Endometrial Cancer
GSK Partner Spotlight
HIV Management
IgG4-Related Disease
Lupus Nephritis
MASH
Pain Management
Type 2 Diabetes
Resources
Atlas of Lumps and Bumps
Case Presentations
Commentary
Disease State and Specialty Directory
FDA Alerts
Multidisciplinary Roundtables
Pearls
Podcasts
Polls
Q&A
Quizzes
Research Summaries
Slideshows
Videos
Featured Conferences
ACR Convergence
AIBD
American Heart Association Scientific Sessions
American Society of Hematology Annual Meeting & Exposition
Consultant360's Practical Updates in Primary Care
Conference on Retroviruses and Opportunistic Infections
Infectious Diseases Society of America’s IDWeek
International AIDS Conference
Society of Hematologic Oncology's Annual Meeting
Clinical Updates
Allergic Asthma
Alzheimer Disease
Cardiovascular Disease
COVID-19
Endometrial Cancer
Endometriosis
Eosinophilic Disorders
Exocrine Pancreatic Insufficiency
Generalized Pustular Psoriasis
Major Depressive Disorder
Nasal Polyps
Ovarian Cancer
Rheumatoid Arthritis
Schizophrenia
Ulcerative Colitis
Uterine Polyps
Publication
About Consultant
Advertising With Consultant360
Author Guidelines
Call for Papers
Case Report Templates
Consultant Current Issue
Consultant Archive
Consultant Early View
FAQ
Get Permissions
Get Permissions
Search
Contact
Login
Menu
Menu
Main navigation
Home
Education
Featured Topics
Acute Hepatic Porphyria
Agitation in Alzheimer Disease
COVID-19
Danon Disease
Depression Care 360
Diabetes
Diabetes Technology
Digital Health Solutions in Diabetes
Dry Eye Disease
Endometrial Cancer
GSK Partner Spotlight
HIV Management
IgG4-Related Disease
Lupus Nephritis
MASH
Pain Management
Type 2 Diabetes
Resources
Atlas of Lumps and Bumps
Case Presentations
Commentary
Disease State and Specialty Directory
FDA Alerts
Multidisciplinary Roundtables
Pearls
Podcasts
Polls
Q&A
Quizzes
Research Summaries
Slideshows
Videos
Featured Conferences
ACR Convergence
AIBD
American Heart Association Scientific Sessions
American Society of Hematology Annual Meeting & Exposition
Consultant360's Practical Updates in Primary Care
Conference on Retroviruses and Opportunistic Infections
Infectious Diseases Society of America’s IDWeek
International AIDS Conference
Society of Hematologic Oncology's Annual Meeting
Clinical Updates
Allergic Asthma
Alzheimer Disease
Cardiovascular Disease
COVID-19
Endometrial Cancer
Endometriosis
Eosinophilic Disorders
Exocrine Pancreatic Insufficiency
Generalized Pustular Psoriasis
Major Depressive Disorder
Nasal Polyps
Ovarian Cancer
Rheumatoid Arthritis
Schizophrenia
Ulcerative Colitis
Uterine Polyps
Publication
About Consultant
Advertising With Consultant360
Author Guidelines
Call for Papers
Case Report Templates
Consultant Current Issue
Consultant Archive
Consultant Early View
FAQ
Get Permissions
Get Permissions
Pediatrics
Resource Center
News
Research Summaries
Resources
FDA Alerts
Pearls of Wisdom
From the Journal
Insights
Commentary
Podcasts
Q&As
Videos
Interactive
Polls
Quizzes
Slideshows
Events & Education
FDA Alerts
FDA Alert
FDA Alert
FDA Approves First Nalmefene Hydrochloride Auto-Injector to Reverse Opioid Overdose
08/23/2024
Anthony Calabro, MA
The first nalmefene hydrochloride auto-injector is another emergency treatment tool to reverse known or suspected opioid overdose.
08/23/2024
FDA Alert
FDA Alert
FDA Approves First Nalmefene Hydrochloride Auto-Injector to Reverse Opioid Overdose
08/23/2024
Anthony Calabro, MA
The first nalmefene hydrochloride auto-injector is another emergency treatment tool to reverse known or suspected opioid overdose.
08/23/2024
FDA Alert
FDA Alert
FDA Approves First Nalmefene Hydrochloride Auto-Injector to Reverse Opioid Overdose
08/23/2024
Anthony Calabro, MA
The first nalmefene hydrochloride auto-injector is another emergency treatment tool to reverse known or suspected opioid overdose.
08/23/2024
FDA Alert
FDA Alert
FDA Approves First Nalmefene Hydrochloride Auto-Injector to Reverse Opioid Overdose
08/23/2024
Anthony Calabro, MA
The first nalmefene hydrochloride auto-injector is another emergency treatment tool to reverse known or suspected opioid overdose.
08/23/2024
FDA Alert
FDA Alert
FDA Approves Epinephrine Nasal Spray for Allergic Reactions, Anaphylaxis
08/19/2024
Anthony Calabro, MA
The nasal spray is the first FDA-approved epinephrine product for the treatment of anaphylaxis not to be administered by injection.
08/19/2024
FDA Alert
FDA Alert
FDA Approves Epinephrine Nasal Spray for Allergic Reactions, Anaphylaxis
08/19/2024
Anthony Calabro, MA
The nasal spray is the first FDA-approved epinephrine product for the treatment of anaphylaxis not to be administered by injection.
08/19/2024
FDA Alert
FDA Alert
FDA Approves Epinephrine Nasal Spray for Allergic Reactions, Anaphylaxis
08/19/2024
Anthony Calabro, MA
The nasal spray is the first FDA-approved epinephrine product for the treatment of anaphylaxis not to be administered by injection.
08/19/2024
FDA Alert
FDA Alert
FDA Approves Epinephrine Nasal Spray for Allergic Reactions, Anaphylaxis
08/19/2024
Anthony Calabro, MA
The nasal spray is the first FDA-approved epinephrine product for the treatment of anaphylaxis not to be administered by injection.
08/19/2024
FDA Alert
FDA Alert
FDA Approves Epinephrine Nasal Spray for Allergic Reactions, Anaphylaxis
08/19/2024
Anthony Calabro, MA
The nasal spray is the first FDA-approved epinephrine product for the treatment of anaphylaxis not to be administered by injection.
08/19/2024
FDA Alert
FDA Alert
FDA Approves Epinephrine Nasal Spray for Allergic Reactions, Anaphylaxis
08/19/2024
Anthony Calabro, MA
The nasal spray is the first FDA-approved epinephrine product for the treatment of anaphylaxis not to be administered by injection.
08/19/2024
Pagination
Previous page
‹‹
Page 3
Next page
››